Pevifoscorvir sodium (ALG-000184)

About Aligos Therapeutics

Aligos Therapeutics is a clinical-stage biotech focused on developing best-in-class therapies for chronic liver and viral diseases, specifically chronic hepatitis B (CHB) and MASH. The company employs a targeted, chemistry-driven approach to design small molecules with optimized pharmacological profiles. Its strategy centers on a lean, experienced team with a proven track record in hepatology and virology drug development, aiming to advance a focused pipeline through key clinical milestones. Despite a challenging financial position with a low market valuation, its progress is defined by upcoming Phase 2 data for its lead assets.

Therapeutic Areas

Other Chronic Hepatitis B (CHB) Drugs